C*lostridium difficile* infection (CDI) is the most common cause of infectious diarrhea in hospitalized patients in the United States of America (USA) and is the most common health care--associated pathogen.[@R1] The Centers for Disease Control and Prevention estimates there are approximately 453,000 cases of CDI per year, 29,300 deaths, and over one billion dollars in health care costs associated with CDI.[@R2],[@R3] One of the most common complications of CDI is recurrence, which occurs in 25% to 33% of patients with primary CDI treated with metronidazole or oral vancomycin.[@R4],[@R5] CDI also decreases a patient's ability to function.[@R6]--[@R8] In patients with chronic diarrhea, such as that associated with HIV infection[@R9] or following kidney transplantation,[@R10] intestinal symptoms may be associated with reduced quality of life including decreased general well-being, satisfaction, social, and physical functioning. The acute effects of antibiotic-associated diarrhea has been shown to impair functional capacity using a clinical estimate of the ability to perform activities of daily living.[@R11] However, patient-specific health-related quality of life (HRQOL) changes including physical, mental, and social health because of CDI have not been studied. These changes may be especially important in patients with recurrent CDI, in whom persistent diarrhea or postinfectious irritable bowel syndrome may cause long-term reduced quality of life.[@R12] An analysis of the literature did not show the existence of any CDI-specific HRQOL instrument. The objective of this study was to develop and validate a disease-specific instrument to assess HRQOL changes related to CDI with a focus on recurrent CDI.

MATERIALS AND METHODS
=====================

Phase I: Development of Candidate Items
---------------------------------------

The stepwise procedure for the elaboration of the *C. difficile* quality-of-life survey is shown in Table [1](#T1){ref-type="table"}. To begin the process, a systematic literature review using a PubMed search was conducted on April 1, 2012 using the search terms "quality of life" and (diarrhea or gastrointestinal or bowel). Items identified from this search were aggregated and tabulated. Acceptability of the items and removal of redundant or unimportant items were done by direct interview of 10 clinicians, including physicians, nurses, infection preventionists, and pharmacists, with expertise in the treatment and care of patients with CDI. The remaining items were tested to assure that the questions did not exceed a sixth grade reading level using the Flesch-Kincaid scale,[@R13] minimized ambiguity or cognitive difficulty; avoided multibarreled questions, were concisely and simply worded, and were easy to translate into other languages. Each survey item was scored on a 5-point Likert scale with a recall period of 7 days. Each item was categorized into one of 3 major domains (physical, mental, or social) based on the subjective theme of the question.
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Stepwise Procedure for the Elaboration of the *Clostridium difficile* Quality of Life Survey
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Structured feedback on the proposed questions was obtained by direct interviews of 5 hospitalized patients with CDI and 5 ambulatory patients with multiple episodes of CDI. An explicit, scripted interview guide was used to elicit feedback on the draft questions items based on the National Institute of Health's Patient Reported Outcomes Measurement Information System (NIH PROMIS) suggested guidelines to evaluate respondent perceptions about language, comprehensibility, ambiguity, and relevance of each item.[@R14],[@R15] A standard set of probes was used as suggested by the PROMIS network. Items for enhancement were discussed after the completion of each set of 5 interviews. This iterative process resulted in stem and response item improvements culminating in a 36-item questionnaire for subsequent psychometric testing. The developed survey was then sent to the social media network (Facebook Inc., Menlo Park, CA) of the Fecal Transplant Foundation (<http://thefecaltransplantfoundation.org/>) for qualitative, anonymous feedback on the survey questions. Ten patients (5 with primary CDI and 5 with recurrent CDI) filled in the survey twice over a period of 4 to 7 days to assess for reproducibility of the survey answers. Ten patients with CDI also completed the survey in the paper format as well as the online survey format to assess the reliability of different survey formats. The online questionnaire was designed to be a minor modification and was not expected to change the content or meanings of items and response scales.[@R16] Intraclass correlation coefficient was calculated for the test-retest procedure and the measurement equivalence between the paper and online form.

Phase II: Clinical Assessment
-----------------------------

The questionnaire was administered along with the widely employed 36-item Short Form 36 (SF-36) Health Survey[@R17] to a cohort of patients with CDI. Inclusion criteria included a positive toxin test for *C. difficile*, signs and symptoms of CDI, and a specific treatment for CDI prescribed by the treating physician. We purposely recruited patients with acute and recurrent CDI. Data collected included demographics, past medical history, number of episodes of CDI, time since last episode of CDI, and current use of antibiotics directed against CDI. Patients were recruited as part of an ongoing observational study in Houston, Texas as previously described.[@R18] In addition, patients were also actively recruited from the social media network of the Fecal Transplant Foundation. The Fecal Transplant Foundation provides support for CDI patients seeking fecal microbiota transplantation. As part of this mission, the Foundation maintains an active social media presence with patients with recurrent CDI. All patients were nonhospitalized while completing the survey. All subjects were asked to answer the questions from the perspective of their prior 7 days of experiences. The study was approved by the Institutional Review Board of the University of Houston. The PI of the study (K.W.G.) had access to the study data and reviewed and approved the final manuscript.

Translation to Other Languages
------------------------------

The English version of the *C. difficile* questionnaire was translated to French using the forward-backward translation method.

Statistical Analysis
--------------------

Each item was transformed to a score between 0 (worst QOL) and 100 (best QOL). Mean±SD was calculated for each item score. Exploratory factor analysis was used to identify item aggregation into subdomains from the 3 major domains (physical, mental, or social) and removal of redundant items. The number of factors chosen within each domain was based on the initial scree test with the percentage of common variance accounted for by a given factor.[@R19] Factor number was chosen based on the Kaiser criteria including an eigenvalue \>1, a break between factors observed on the scree plot, and factor loading \>0.4.[@R20] Item aggregation and reduction was chosen using a promax rotation as a measure of orthogonal rotation assuming correlation between items within subdomains. Final subdomains were chosen based on these analyses coupled with the conceptual meaning of each item. Interitem and item to scale correlation was measured using the Pearson correlation coefficient. Internal consistency was measured for each domain and total scale using Cronbach α reliability coefficient.

Demographics and CDI disease variables were compared between CDI patients stratified by primary CDI only compared with patients that experienced recurrent CDI. Variables were compared using the Pearson χ^2^ test for categorical variables and Student *t* test for continuous variables. Correlation between subdomains of the *C. difficile* questionnaire was compared with the corresponding SF-36 subscales. Mean differences in quality-of-life scores in patients with primary versus recurrent CDI were assessed using the Student *t* test. Finally, mean score parameter changes of the overall *C. difficile* quality-of-life score and the major domains along with the corresponding subscales of the SF-36 using multivariate linear regression. Any demographic or CDI disease variable that was different between patients with primary versus recurrent disease (defined as a *P*\<0.2 in the univariate analysis) was included in the multivariate model. SAS version 9.3 (SAS Institute, Cary NC) or IBM SPSS Statistics version 22 (IBM, Armonk, NY) was used for all analyses. A *P* value \<0.05 was considered significant for inferential statistics.

RESULTS
=======

The literature search identified 12,380 citations which were reduced to 1364 citations using limits clinical trials, publications with 10 years, humans, and English language. The citations were screened for information about gastrointestinal or general quality-of-life questionnaires or rating scales that could contribute questions for a new QOL scale. Twenty-five relevant QOL surveys were identified of which 15 were available for review.[@R21]--[@R33] From a review of these surveys, 72 separate items were identified and categorized as referring to physical, social, or mental QOL facets. Ten patients with CDI, 10 clinicians with expertise on the care of CDI patients, and 10 non-CDI healthy subjects were given the questionnaire on the relevance of the questions through a face-to-face interview. On the basis of the results of these interviews, some items were reformulated and the number of total items was reduced to 36 questions. The 36-item questionnaire was then given to 10 patients with CDI twice at an interval between 4 to 7 days. Intraclass correlation coefficient for test-retest was 0.92 for patients with primary CDI (n=5) and 0.95 for patients with recurrent CDI (n=5). Completion of the electronic survey and the paper survey was also completed by 10 patients with CDI. Intraclass correlation coefficient between the paper and electronic version was 0.99.

Clinical Assessment
-------------------

Ninety-eight patients affected with CDI aged 52±16 years (female: 78%; white: 88%) were recruited and completed the *C. difficile* questionnaire of whom 76 completed the SF-36. Twenty-two patients (22%) were currently taking *C. difficile* antibiotics, most commonly oral vancomycin (16%), metronidazole (5%), or fidaxomicin (1%). Twenty-seven patients (28%) had experienced only a primary case of CDI. Patients had experienced an average of 2.6±2.6 recurrences (range, 0 to 14). The average time since CDI diagnosis was 4.2±1.8 months. Patients with recurrent CDI were more likely to be female (89%) as compared with patients with primary CDI (52%; *P*\<0.001) and were less likely to have been hospitalized in the previous 3 months (*P*=0.026). There were no significant differences in age or past medical history between patients with primary or recurrent CDI.

Domains, subdomains, questions, and item analysis for the survey are shown in Table [2](#T2){ref-type="table"}. The scree test identified 2 factors in the physical and mental domains had an eigenvalue \>1 with an associated drop in the scree plot after factor 2 (Fig. [1](#F1){ref-type="fig"}). For the social domain, 1 factor had an eigenvalue \>1 with an associated drop in the scree plot after factor 1. For the physical domain, factors 1 and 2 explained 64.2% and 8.7% of the variance, respectively, resulting in 72.9% of the variance explained by both factors. For the mental domain, factors 1 and 2 explained 60.3% and 8.7% of the variance, respectively, resulting in 69.0% of the variance explained by both factors. For the social domain, factor 1 explained 61.8% of the variance. All items showed a factor loading of \>0.5 to at least one of the factors. Factor analysis and domain structure is shown in Supplemental Table 1, Supplemental Digital Content 1, <http://links.lww.com/JCG/A218>. Results of the exploratory factorial analysis identified 2 subdomains for physical QOL categorized as general physical complaints or specific physical complaints related to the CDI. Two subdomains for mental QOL were also identified and categorized as anxiety of future complications of CDI and anxiety of current mental health related to CDI. One domain for social was identified and categorized as relationships. Scale reliability and content of the *C. difficile* questionnaire is shown in Table [3](#T3){ref-type="table"}. Internal consistency measured with Cronbach α was ≥0.87 for all domains and subdomains. Interitem and item to scale correlation is shown in Supplemental Table 2, Supplemental Digital Content 1, <http://links.lww.com/JCG/A218>.
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Scale Reliability and *Clostridium difficile* Survey Content (32 Items, 3 Major Domains, and 4 Subdomains)
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To measure concurrent validity, the overall, physical, and mental domains of the *C. difficile* questionnaire were compared with the physical and mental component summaries of the SF-36. All 5 of these domains were significantly correlated (*P*\<0.001) using the Spearman rank-correlation coefficients (correlation coefficient range, 0.67 to 0.91). The overall *C. difficile* quality-of-life score was more highly correlated with the *C. difficile* physical (0.91) and *C. difficile* mental scores (0.91) than the SF-36 physical (0.63) or SF-36 mental (0.78) scores. Overall and major domains of the *C. difficile* questionnaire and the SF-36 physical and mental component summaries quality-of-life scores decreased in patients with recurrent CDI compared with patients with primary CDI (Fig. [2](#F2){ref-type="fig"}). All results were statistically significant (*P*\<0.001) except for the SF-36 physical component scores (*P*=0.11). Separate multivariate linear regression models were built to assess parameter estimate changes for the overall and major domains of the *C. difficile* questionnaire and the SF-36 physical and mental component summaries quality-of-life scores (Table [4](#T4){ref-type="table"}). Gender and previous hospitalization were included in all models based on the univariate analysis. Quality-of-life scores consistently decreased with increasing number of CDI episodes and improved with increasing time since last episode. *C. difficile* overall and major domains scores displayed greater mean changes in parameter estimates compared with the SF-36 physical or mental component scores. The French language translation for the Cdiff32 is shown in Supplemental Table 3, Supplemental Digital Content 1, <http://links.lww.com/JCG/A218>.
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Multivariate Model to Assess Changes in *Clostridium difficile* Questionnaire and SF-36 Quality-of-Life Scores Stratified by Number of CDI Episodes, Time Since Last Episode, and Other Confounders
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DISCUSSION
==========

Patient-reported outcomes are increasingly recognized as important endpoints for clinical research. In Europe, \>50% of the regulatory documents for approval of new pharmaceuticals include guidance for the use of patient-reported outcomes in the approval process.[@R34] Although a number of gastrointestinal quality-of-life surveys exist, no equivalent HRQOL instrument exists for CDI. Therefore, the aim of this study was to develop a disease-specific scale able to measure quality-of-life differences in patients with CDI. In this study, we designed and validated the Cdiff32 HRQOL survey using an established method for scale development and validation.

In phase I of the study, we identified previous published QOL studies that had been applied to patients with gastrointestinal illness. All unique questions identified by this search were tabulated and categorized into physical, mental, and social domains to allow for future collaborative work with the NIH PROMIS initiative.[@R35] All questions were reformulated onto a common 5-point Likert scale and assessed for comprehension and ease of use. Using focus group discussions with CDI patients and clinician experts, the number of items in the questionnaire was reduced to 36 questions. Test-retest and paper to electronic measurement equivalence were all acceptable.

Next, exploratory factor analysis was used to identify relevant subdomains and also reduced the total number of questions to 32. Two subscales were identified for the physical and mental domain. The overall survey, domains, and subdomains showed high internal consistency using Cronbach α coefficient analysis. Construct validity analysis showed a strong correlation with the SF-36 physical and mental components. Finally, the Cdiff32 and major subdomains were superior to the SF-36 at identifying differences in quality of life between CDI patients with primary compared with recurrent CDI.

Despite following scientifically appropriate psychometric methods, this study has certain limitations. This study was developed in the context of an observational trial and validated using an anonymous survey. The utility of the Cdiff32 to measure changes based on drug therapy or other targeted interventions will require future randomized-controlled studies, especially with larger sample sizes. The study was developed and validated only by English-speaking scientists and patients. Language translations and cultural nuances will need to be tested in the appropriate language and cultural populations. The study was not powered to identify differences in the subdomains identified in the development of the instrument. Future research will be needed to assess validity of these subdomains of the Cdiff32. Finally, although the major domains of the Cdiff32 were chosen to correlate with the PROMIS initiative, the correlation of the Cdiff32 domains scores with PRO questions from the PROMIS database will require further study.

In summary, this study developed and validated the Cdiff32, a multilanguage HRQOL instrument to be used in patients with CDI. The questionnaire should be evaluated for value in other forms of enteric infection and disease.
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